We're sharing resources and data with these authorities to help them develop estimates for manufacturing capability, timing of possible production, and use of adjuvant technology in production of a potential pandemic vaccine. (Adjuvants are the parts of a vaccine that help the body respond more effectively to it. Sort of like adding a shot of espresso to your iced coffee.)
This week, GSK has been in continuous discussions with the World Health Organization, the US Centers for Disease Control and Prevention, the US Department of Health and Human Services, and the European Centre for Disease Prevention and Control to gain a better understanding of the new influenza A (H1N1) strain. (Remember--we're not calling it swine flu anymore.)
GSK has an active pandemic influenza vaccine R&D program which includes development of pre-pandemic and pandemic vaccines and use of novel technology, such as adjuvants systems.
GSK stands ready to begin manufacture of a potential vaccine against the new influenza A (H1N1) strain virus once the WHO and other public health authorities make recommendations for composition of the vaccine.
In the meantime...sneeze into the crook of your arm and wash your hands often, folks!
(Images courtesy of CDC's Public Health image Library.)
Leave a comment